New MRI dye could reveal hidden inflammation in stroke Patients' brain arteries
NCT ID NCT03084523
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 27 times
Summary
This study tested a special MRI contrast agent called ferumoxytol to see if it can detect inflammation in the walls of brain arteries in people who recently had a stroke. The researchers compared it to a standard MRI contrast to see which one better shows artery inflammation. The goal is to improve how doctors identify high-risk patients and prevent future strokes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STROKE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Yale University
New Haven, Connecticut, 06510, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ferumoxytol (Feraheme) as an MRI contrast agent
What this could lead to
If successful, this could help doctors identify inflamed brain arteries more accurately, leading to better treatments to prevent repeat strokes.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply to everyone. The new MRI method may not prove better than existing techniques.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.